Literature DB >> 19255765

[Periodic fever syndrome/autoinflammatory syndrome].

I Kötter1, J Schedel, J B Kümmerle-Deschner.   

Abstract

Hereditary periodic fever syndromes (autoinflammatory syndromes) are characterised by relapsing fevers and additional manifestations such as skin rashes, mucosal manifestations, and joint pain. Some of these disorders only present with organ manifestations and serological signs of inflammation without obvious fever (e.g. PAPA and Blau syndrome). There is a strong serological inflammatory response with an elevation of serum amyloid A (risk of secondary amyloidosis). There are monogenic disorders for which the mode of inheritance and gene mutation are known, but probably also polygenic diseases which present with similar symptoms to the classic autoinflammatory syndromes. Gene mutations have been described for the monogenic disorders (FMF, HIDS, CAPS, PAPA and Blau syndrome), which lead to an induction of the production of IL-1ss. Therapeutically, the IL-1-receptor antagonist anakinra is mainly used. In the case of TRAPS and Blau syndrome, TNF antagonists may also be used. PFAPA syndrome, the Schnitzler syndrome, Still's disease of adult and pediatric onset, Behçet's disaese and Crohn's disease also are mentioned as additional possible autoinflammatory syndromes.

Entities:  

Mesh:

Year:  2009        PMID: 19255765     DOI: 10.1007/s00393-009-0449-z

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  71 in total

1.  Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome.

Authors:  E Drewe; M L Huggins; A G Morgan; M J D Cassidy; R J Powell
Journal:  Rheumatology (Oxford)       Date:  2004-08-17       Impact factor: 7.580

2.  Schnitzler syndrome: a case report of successful treatment using the anti-CD20 monoclonal antibody rituximab.

Authors:  K M Ramadan; H A Eswedi; M R El-Agnaf
Journal:  Br J Dermatol       Date:  2007-03-13       Impact factor: 9.302

3.  Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient.

Authors:  I Mitroulis; V P Papadopoulos; T Konstantinidis; K Ritis
Journal:  Neth J Med       Date:  2008-12       Impact factor: 1.422

Review 4.  Familial autoinflammatory diseases: genetics, pathogenesis and treatment.

Authors:  Silvia Stojanov; Daniel L Kastner
Journal:  Curr Opin Rheumatol       Date:  2005-09       Impact factor: 5.006

5.  Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.

Authors:  Melike Melikoglu; Izzet Fresko; Cem Mat; Yilmaz Ozyazgan; Feride Gogus; Sebahattin Yurdakul; Vedat Hamuryudan; Hasan Yazici
Journal:  J Rheumatol       Date:  2005-01       Impact factor: 4.666

6.  Blau syndrome mutation of CARD15/NOD2 in sporadic early onset granulomatous arthritis.

Authors:  Carlos D Rosé; Trudy M Doyle; Gail McIlvain-Simpson; Jessica E Coffman; James T Rosenbaum; Michael P Davey; Tammy M Martin
Journal:  J Rheumatol       Date:  2005-02       Impact factor: 4.666

7.  Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.

Authors:  Hal M Hoffman; Martin L Throne; N J Amar; Mohamed Sebai; Alan J Kivitz; Arthur Kavanaugh; Steven P Weinstein; Pavel Belomestnov; George D Yancopoulos; Neil Stahl; Scott J Mellis
Journal:  Arthritis Rheum       Date:  2008-08

Review 8.  The use of interferon alpha in Behçet disease: review of the literature.

Authors:  Ina Kötter; Ilhan Günaydin; Manfred Zierhut; Nicole Stübiger
Journal:  Semin Arthritis Rheum       Date:  2004-04       Impact factor: 5.532

9.  Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome.

Authors:  Nobuo Kanazawa; Ikuo Okafuji; Naotomo Kambe; Ryuta Nishikomori; Mami Nakata-Hizume; Sonoko Nagai; Akihiko Fuji; Takenosuke Yuasa; Akira Manki; Yoshihiko Sakurai; Mitsuru Nakajima; Hiroko Kobayashi; Ikuma Fujiwara; Hiroyuki Tsutsumi; Atsushi Utani; Chikako Nishigori; Toshio Heike; Tatsutoshi Nakahata; Yoshiki Miyachi
Journal:  Blood       Date:  2004-09-30       Impact factor: 22.113

10.  Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome.

Authors:  Kazuki Takada; Ivona Aksentijevich; Vijayabhanu Mahadevan; Jane A Dean; Richard I Kelley; Daniel L Kastner
Journal:  Arthritis Rheum       Date:  2003-09
View more
  4 in total

1.  Clinical utility gene card for: prototypic hereditary recurrent fever syndromes (monogenic autoinflammatory syndromes).

Authors:  Martina Witsch-Baumgartner; Isabelle Touitou
Journal:  Eur J Hum Genet       Date:  2014-11-19       Impact factor: 4.246

2.  [IL-1 antagonists].

Authors:  I Kötter; G Horneff
Journal:  Z Rheumatol       Date:  2010-09       Impact factor: 1.372

3.  [Interleukin-1-mediated diseases].

Authors:  D Holzinger; H Becker; A M Jacobi
Journal:  Internist (Berl)       Date:  2013-04       Impact factor: 0.743

Review 4.  Monogenic autoinflammatory diseases in adults - a challenge to rheumatologic practice at the onset of the Polish national programme of interleukin 1 inhibitor treatment.

Authors:  Marcin Milchert; Joanna Makowska; Olga Brzezińska; Marek Brzosko; Ewa Więsik-Szewczyk
Journal:  Reumatologia       Date:  2019-12-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.